L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:365250 CAPLUS Full-text
DN 144:412529
TI Preparation of lactam compounds useful as protein kinase inhibitors
IN Blackburn, Christopher; Claiborne, Christopher F.; Cullis, Courtney A.; Dales, Natalie A.; Patane, Michael A.; Stirling, Matthew; Stradella, Omar G.; Weatherhead, Gabriel S.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2006041773 | A2 | 20060420 | WO 2005-US35458 | 20051003 |
| | WO 2006041773 | A3 | 20060518 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | AU 2005294575 | A1 | 20060420 | AU 2005-294575 | 20051003 |
| | CA 2582235 | A1 | 20060420 | CA 2005-2582235 | 20051003 |
| | US 20060100194 | A1 | 20060511 | US 2005-242413 | 20051003 |
| | US 7459448 | B2 | 20081202 | | |
| | EP 1799684 | A2 | 20070627 | EP 2005-812472 | 20051003 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| | CN 101068815 | A | 20071107 | CN 2005-80041429 | 20051003 |
| | JP 2008515798 | T | 20080515 | JP 2007-534851 | 20051003 |
| | IN 2007DN02613 | A | 20070803 | IN 2007-DN2613 | 20070409 |
| | US 20090105213 | A1 | 20090423 | US 2008-231661 | 20080904 |
| PRAI | US 2004-615761P | P | 20041004 | | |
| | US 2005-242413 | A3 | 20051003 | | |
| | WO 2005-US35458 | W | 20051003 | | |

OS CASREACT 144:412529; MARPAT 144:412529
GI



AB The title compds. I [ring A is (un)substituted 5-6 membered (hetero)aryl; G1 = CO, CS, SO2; Y1 = N or CH and Y2 = N or CR5 (provided that at least one of Y1 and Y2 is N); R1 = H, alkyl, aryl, etc.; R2 = alkyl, (hetero)aryl, heterocyclyl; R3 = H, F, alkyl, etc.; R4 = H, F, alkyl, fluoroalkyl; or R3 and R4, taken together with the carbon atom to which they are attached, form (un)substituted 3-6 membered carbocyclyl; R5 = H, halo, NO2, etc.; and their pharmaceutically acceptable salts], useful as inhibitors of protein kinases, were prepared Thus, reacting 4-dimethylaminomethylene-7-iodo-3,4-dihydro-1H-benzo[b]azepine-2,5-dione (preparation given) with 1-(3,4-dimethoxyphenyl)guanidine in the presence of K2CO3 in EtOH afforded 81% II. Compds. I were tested against Aurora A, Aurora B, Chk-1 and PLK1 kinases (data given). The invention also provides pharmaceutical compns. comprising the compds. I and methods of using the compns. in the treatment of various diseases such as cancer.

IT 884197-44-8P 884197-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of lactam compds. as protein kinase inhibitors)

RN 884197-44-8 CAPLUS

CN 1H-1-Benzazepine-2,5-dione, 8-chloro-1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3,4-dihydro- (CA INDEX NAME)



RN 884197-45-9 CAPLUS

CN 1H-1-Benzazepine-2,5-dione, 8-chloro-1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-4-[(dimethylamino)methylene]-3,4-dihydro- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1341981 CAPLUS Full-text
DN 144:233030
TI Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: Quinoline(di)one and benzazepine(di)one derivatives
AU Geneste, Herve; Backfisch, Gisela; Braje, Wilfried; Delzer, Juergen; Haupt, Andreas; Hutchins, Charles W.; King, Linda L.; Lubisch, Wilfried; Steiner, Gerd; Teschendorf, Hans-Juergen; Unger, Liliane; Wernet, Wolfgang
CS Discovery Research, Abbott GmbH & Co. KG, Ludwigshafen, D-67008, Germany
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(3), 658-662
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:233030
AB The synthesis and SAR of novel and selective dopamine D3-receptor antagonists based on a 3,4-dihydro-1H-quinolin-2-one, a 1,3,4,5-tetrahydro-benzo[b]azepin-2-one, 1H-quinoline-2,4-dione or a 3,4-dihydro-1H-benzo[b]azepine-2,5-dione scaffold are discussed. A-706149 [i.e., 1-[4-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4- yl]piperazinyl]butyl]-3,4-dihydro-1H-1-benzazepine-2,5-dione] (2.15 mg/kg, po) antagonizes PD 128907-induced huddling deficits in rat, a social interaction paradigm.
IT 855782-41-1, 1-[4-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione
855782-44-4, 1-[4-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-7,8-dimethoxy-3,4-dihydro-1H-1-benzazepin-2,5-dione
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of [[tert-butyl(trifluoromethyl)pyrimidinyl]piperazinyl]alkyl]quinolinone and study of their activity as selective dopamine D3-receptor antagonists in comparison with benzazepinone and benzazepine dione analogs and derivs.)
RN 855782-41-1 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-44-4 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:540577 CAPLUS Full-text
DN 143:78097
TI Preparation of ketolactams as dopamine D3 receptor modulators
IN Lubisch, Wilfried; Haupt, Andreas; Braje, Wilfried; Geneste, Herve
PA Abbott G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005056546 | A1 | 20050623 | WO 2004-EP14118 | 20041210 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 10358004 | A1 | 20050714 | DE 2003-10358004 | 20031211 |
| | CA 2548276 | A1 | 20050623 | CA 2004-2548276 | 20041210 |
| | EP 1692129 | A1 | 20060823 | EP 2004-803759 | 20041210 |
| | EP 1692129 | B1 | 20080820 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| | JP 2007513915 | T | 20070531 | JP 2006-543500 | 20041210 |
| | AT 405558 | T | 20080915 | AT 2004-803759 | 20041210 |
| | ES 2313110 | T3 | 20090301 | ES 2004-803759 | 20041210 |
| | MX 2006006092 | A | 20060811 | MX 2006-6092 | 20060530 |
| | US 20070219182 | A1 | 20070920 | US 2007-582285 | 20070410 |
| PRAI | DE 2003-10358004 | A | 20031211 | | |
| | WO 2004-EP14118 | W | 20041210 | | |

OS MARPAT 143:78097
GI




I II




III

AB Title compds. I [R1, R2 = H, halo, alkyl, etc.; R3, R4 = H, halo, alkyl, etc.; A = N with provisos; B = C(RmRn); D = alkylene with provisos; Z = (un)saturated monocyclic nitrogen heterocycle; Rm, Rn = H, halo, alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For

example, N-alkylation of 3,4-dihydro-1H-2-benzazepin-1,5(2H)-dione with chloropropyl II, afforded benzazepindione III. In dopamine D3 receptor affinity assays, 8-examples of compds. I exhibited Ki values ranging from 56-296 nM. Compds. I are claimed to be particularly suited for the treatment of diseases that respond to the modulation of the dopamine D3 receptor.

IT 855782-40-0P, 1-[3-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]propyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-41-1P, 1-[4-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-42-2P, 1-[(2E)-4-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]but-2-enyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-44-4P, 1-[4-[4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-7,8-dimethoxy-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-45-5P 855782-46-6P 855782-47-7P 855782-48-8P 855782-49-9P, 1-[4-[4-(2-tert-Butyl-6-isopropylpyrimidin-4-yl)piperazin-1-yl]butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-54-6P 855782-57-9P, 1-[4-(7-Propionyl-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-58-0P, 1-[4-(6-Chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-60-4P 855782-61-5P 855782-62-6P, 1-[4-(4-Ethylpiperazin-1-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-63-7P 855782-64-8P, 1-[4-(2,4,6-Trimethylpiperazin-1-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855782-65-9P, 1-[4-(4-Propylpiperazin-1-yl)butyl]-3,4-dihydro-1H-benzo[b]azepin-2,5-dione 855782-66-0P 855782-67-1P 855782-68-2P 855782-69-3P 855782-70-6P, 1-[4-(4-Ethylpiperazin-1-yl)-4-oxobutyl]-3,4-dihydro-1H-benzo[b]azepin-2,5-dione 855782-72-8P 855782-74-0P 855782-77-3P 855782-79-5P 855782-82-0P 855782-85-3P 855782-88-6P 855782-91-1P 855782-93-3P 855782-96-6P 855782-99-9P 855783-01-6P 855783-03-8P 855783-05-0P 855783-07-2P 855783-09-4P 855783-11-8P 855783-13-0P 855783-15-2P 855783-17-4P 855783-19-6P 855783-21-0P 855783-23-2P 855783-25-4P 855783-27-6P 855783-29-8P 855783-31-2P 855783-33-4P 855783-35-6P 855783-36-7P, 1-[4-(4-Allylpiperazin-1-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855783-37-8P, tert-Butyl 4-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl]piperazin-1-carboxylate 855783-38-9P, 1-(4-Piperazin-1-yl-butyl)-3,4-dihydro-1H-1-benzazepin-2,5-dione 855783-39-0P 855783-40-3P, 1-[4-(Hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)butyl]-3,4-dihydro-1H-1-benzazepin-2,5-dione 855783-41-4P, Benzyl (1R,5R)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptan-3-carboxylate 855783-42-5P 855783-43-6P, Benzyl (1S,5S)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptan-3-carboxylate 855783-44-7P 855782-46-9P 855783-47-0P 855783-48-1P 855783-51-6P 855783-53-8P 855783-55-0P, 1-[4-(Octahydropyrido[1,2-a][1,4]diazepin-2-yl)butyl]-3,4-dihydro-1H-benzo[b]azepin-2,5-dione 855783-57-2P 855783-58-3P, 1-(4-Piperidin-1-yl-butyl)-3,4-dihydro-1H-1-benzazepin-2,5-dione Hydrochloride 855783-60-7P 855783-62-9P 855783-64-1P 855783-66-3P 855783-68-5P 855783-70-9P 855783-71-0P, 1-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-3,4-dihydro-1H-

benzo[b]azepin-2,5-dione 855783-73-2P 855783-76-5P
855783-78-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of ketolactams as dopamine D3 receptor modulators)

RN 855782-40-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-41-1 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-42-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[(2E)-4-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]-2-buten-1-yl]-3,4-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 855782-44-4 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 855782-45-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-propyl-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-, hydrochloride (1:?) (CA INDEX NAME)



RN 855782-46-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[6-cyclobutyl-2-(1,1-dimethylethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 855782-47-7 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-methyl-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 855782-48-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2,6-bis(1,1-dimethylethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro-, hydrochloride (1:?) (CA INDEX NAME)




x HCl

RN 855782-49-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(1,1-dimethylethyl)-6-(1-methylethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)




RN 855782-54-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[6-cyclopropyl-2-(1,1-dimethylethyl)-4-pyrimidinyl]-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-57-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[3,4-dihydro-7-(1-oxopropyl)-2(1H)-isoquinolinyl]butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-58-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-60-4 CAPLUS
CN 6-Isoquinolinecarbonitrile, 1,2,3,4-tetrahydro-2-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-59-1
CMF C24 H25 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-61-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-methyl-1-piperazinyl)butyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 855782-62-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-ethyl-1-piperazinyl)butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-63-7 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(2-methylpropyl)-1-piperazinyl]butyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 855782-64-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(2,4,6-trimethyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 855782-65-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-propyl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 855782-66-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[(3R)-3-methyl-1-piperazinyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855782-67-1 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(3R)-4-ethyl-3-methyl-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855782-68-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[(3S)-3-methyl-1-piperazinyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855782-69-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(3S)-4-ethyl-3-methyl-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855782-70-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-ethyl-1-piperazinyl)-4-oxobutyl]-3,4-dihydro- (CA INDEX NAME)



RN 855782-72-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(1-methylethyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-71-7
CMF C21 H31 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-74-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(1-methylpropyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-73-9
CMF C22 H33 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-77-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(1-methylbutyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-76-2
CMF C23 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-79-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-butyl-1-piperazinyl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-78-4
CMF C22 H33 N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 855782-82-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(1-ethylpropyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-81-9
CMF C23 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-85-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-cyclopentyl-1-piperazinyl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-84-2
CMF C23 H33 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-88-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-cyclohexyl-1-piperazinyl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-87-5
CMF C24 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-91-1 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(3-cyclohexylpropyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX

NAME)

CM 1

CRN 855782-90-0
CMF C27 H41 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-93-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(cyclohexylmethyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-92-2
CMF C25 H37 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-96-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(2-cyclohexylethyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-95-5
CMF C26 H39 N3 O2

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855782-99-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[(tetrahydro-2-furanyl)methyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855782-98-8
CMF C23 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-01-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(phenylmethyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-00-5
CMF C25 H31 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-03-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-(1H-pyrrol-2-yl)ethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-02-7
CMF C24 H32 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-05-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-(1H-imidazol-2-yl)ethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-04-9
CMF C23 H31 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-07-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-(2-thienyl)ethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-06-1
CMF C24 H31 N3 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-09-4 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(2-methoxyethyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-08-3
CMF C21 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-11-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(3-methoxypropyl)-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-10-7
CMF C22 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-13-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(2-ethoxyethyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-12-9
CMF C22 H33 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-15-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-14-1
CMF C22 H34 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-17-4 CAPLUS
CN 1-Piperazinebutanenitrile, 4-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-16-3
CMF C22 H30 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-19-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-(2-oxo-1-pyrrolidinyl)ethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-18-5
CMF C24 H34 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-21-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-20-9
CMF C24 H34 N4 O4

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-23-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[2-oxo-2-(1-piperidinyl)ethyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-22-1
CMF C25 H36 N4 O3

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-25-4 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(cyclopropylcarbonyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-24-3
CMF C22 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-27-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(4-acetyl-1-piperazinyl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-26-5
CMF C20 H27 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-29-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-28-7
CMF C23 H31 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-31-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(2-furanylcarbonyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-30-1
CMF C23 H27 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-33-4 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(ethylsulfonyl)-1-piperazinyl]butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-32-3
CMF C20 H29 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-35-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 855783-34-5
CMF C20 H29 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-36-7 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[4-(2-propen-1-yl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 855783-37-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 855783-38-9 CAPLUS

CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(1-piperazinyl)butyl]- (CA INDEX NAME)



RN 855783-39-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-40-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855783-41-4 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-3-carboxylic acid, 6-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, phenylmethyl ester, (1R,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-42-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(1S,5R)-3,6-diazabicyclo[3.2.0]hept-6-ylbutyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-43-6 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-3-carboxylic acid, 6-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, phenylmethyl ester, (1S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-44-7 CAPLUS

CN 1H-1-Benzazepine-2,5-dione, 1-[4-(1R,5S)-3,6-diazabicyclo[3.2.0]hept-6-ylbutyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-46-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(1R,5S)-3-ethyl-3,6-diazabicyclo[3.2.0]hept-6-yl]butyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-47-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-[(1S,5R)-3-methyl-3,6-diazabicyclo[3.2.0]hept-6-yl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-49-2 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-[4-(2,3,4,5-tetrahydro-2,5-dioxo-1H-1-benzazepin-1-yl)butyl]-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 855783-51-6 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]butyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-53-8 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]butyl]-3,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-55-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(octahydropyrido[1,2-a][1,4]diazepin-2(3H)-yl)butyl]- (CA INDEX NAME)



RN 855783-57-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]butyl]-3,4-dihydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 855783-58-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(1-piperidinyl)butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 855783-60-7 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-methyl-1-piperidinyl)butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-59-4
CMF C20 H28 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-62-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-(hexahydro-1H-azepin-1-yl)butyl]-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-61-8
CMF C20 H28 N2 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-64-1 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(3-methyl-1-piperidinyl)butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-63-0
CMF C20 H28 N2 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 855783-66-3 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-propyl-1-piperidinyl)butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-65-2
CMF C22 H32 N2 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 855783-68-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-morpholinyl)butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-67-4
CMF C18 H24 N2 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-70-9 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 3,4-dihydro-1-[4-(4-thiomorpholinyl)butyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855783-69-6
CMF C18 H24 N2 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 855783-71-0 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyl]-3,4-dihydro- (CA INDEX NAME)



RN 855783-73-2 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl]butyl]-3,4-dihydro-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 855783-72-1
CMF C25 H29 Cl2 N3 O2

PAGE 1-A



PAGE 2-A

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 855783-76-5 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-(3,5-dichlorophenyl)-1-piperazinyl]butyl]-3,4-dihydro-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 855783-75-4
CMF C24 H27 Cl2 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 855783-78-7 CAPLUS
CN 1H-1-Benzazepine-2,5-dione, 1-[4-[4-[3,5-bis(trifluoromethyl)phenyl]-1-piperazinyl]butyl]-3,4-dihydro-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 855783-77-6
CMF C26 H27 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:844929 CAPLUS Full-text
DN 135:366727
TI Benzazepine derivatives as inhibitors of hyperproliferation diseases
IN Goldstein, Steven W.; Longo, Kelly P.; Nagel, Arthur A.; Lowe, John A., III
PA Pfizer Inc., USA
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 6319915 | B1 | 20011120 | US 2000-548194 | 20000413 |
| PRAI US 1999-151137P | P | 19990827 | | |

OS MARPAT 135:366727
GI



I

AB A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the formula I or a pharmaceutically acceptable salt, hydrate or prodrug thereof: wherein R1 = CO2H, SO2H, PO3H, etc. ; R2 = H or benzotriazolyl derivative, etc.; R3 and R4 = H, alkyl, Ph, etc.; W = OH or amino derivative; X, Y, and Z = O, S, CH2, SO, SO2, etc.; and t = 1-5.

IT 374539-14-7 374539-15-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)(benzazepine derivs. as inhibitors of hyperproliferation diseases such as cancer)

RN 374539-14-7 CAPLUS
CN Urea, N-[7-fluoro-2,3,4,5-tetrahydro-2,5-dioxo-1-[2-oxo-2-(3,3,5,5-tetramethyl-1-piperidinyl)ethyl]-1H-1-benzazepin-3-yl]-N'-[3-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)



RN 374539-15-8 CAPLUS
CN Urea, N-[7-fluoro-2,3,4,5-tetrahydro-2,5-dioxo-1-[2-oxo-2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]-1H-1-benzazepin-3-yl]-N'-[3-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:383927 CAPLUS Full-text
DN 133:34425
TI Pharmaceutical compositions containing N-substituted azaheterocyclic compounds for the treatment of indications related to angiogenesis
IN Hansen, Anker Jon; Jorgensen, Tine Krogh; Olsen, Uffe Bang
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2000032193 | A1 | 20000608 | WO 1999-DK671 | 19991201 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1135129 | A1 | 20010926 | EP 1999-957964 | 19991201 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2003524611 | T | 20030819 | JP 2000-584888 | 19991201 |
| US 20020045610 | A1 | 20020418 | US 2001-872127 | 20010601 |
| PRAI DK 1998-1586 | A | 19981202 | | |
| US 1998-111445P | P | 19981208 | | |
| WO 1999-DK671 | W | 19991201 | | |

OS MARPAT 133:34425
AB The present invention relates to the use of N-substituted azaheterocyclic compds. or salts thereof, for the treatment of conditions related to angiogenesis. N-substituted azaheterocyclic compds. decreased the vessel area of neovascularization of mouse cornea by 30-50%. A tablet contained a N-substituted azaheterocyclic compound 100, silicone dioxide 1.5, microcryst. cellulose 70, modified cellulose gum 7.5, in the core, and hydroxypropyl Me cellulose 9, and Mywacett 9-40T 0.9 mg in the coating.
IT 183614-69-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)(pharmaceutical compns. containing N-substituted azaheterocyclic compds. for treatment of indications related to angiogenesis)
RN 183614-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[3-(6,11-dihydro-6,11-dioxo-5H-dibenz[b,e]azepin-5-yl)propyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:713004 CAPLUS Full-text
DN 126:8146
OREF 126:1815a,1818a
TI Novel heterocyclic compounds for treatment of pain and/or inflammation
IN Joergensen, Tine Krogh; Andersen, Knud Erik; Andersen, Henrik Sune; Hohlweg, Rolf; Madsen, Peter; Olsen, Uffe Bang
PA Novo Nordisk A/s, Den.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9631497 | A1 | 19961010 | WO 1996-DK138 | 19960401 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML | | | | |
| | US 5698551 | A | 19971216 | US 1996-623807 | 19960329 |
| | CA 2217206 | A1 | 19961010 | CA 1996-2217206 | 19960401 |
| | AU 9651002 | A | 19961023 | AU 1996-51002 | 19960401 |
| | EP 820450 | A1 | 19980128 | EP 1996-907326 | 19960401 |
| | EP 820450 | B1 | 20010912 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| | JP 11503126 | T | 19990323 | JP 1996-529867 | 19960401 |
| | AT 205489 | T | 20010915 | AT 1996-907326 | 19960401 |
| | ZA 9602738 | A | 19961024 | ZA 1996-2738 | 19960404 |
| | IN 1996MA00557 | A | 20050304 | IN 1996-MA557 | 19960404 |
| | US 5747481 | A | 19980505 | US 1997-863749 | 19970527 |
| | US 5750518 | A | 19980512 | US 1997-863751 | 19970527 |
| | US 5780486 | A | 19980714 | US 1997-863257 | 19970527 |
| | US 5846968 | A | 19981208 | US 1997-863746 | 19970527 |
| PRAI | DK 1995-403 | A | 19950407 | | |
| | DK 1995-1006 | A | 19950911 | | |
| | US 1996-623807 | A3 | 19960329 | | |
| | WO 1996-DK138 | W | 19960401 | | |

OS MARPAT 126:8146
GI



I



II

AB Compds. I [R1, R2 = H, halo, CF3, OH, alkyl, alkoxy; Y = various trivalent branched radicals: CH2N(CH2), CON(CH2), (CH2)NCO, CH:C(CH2), OCH(CH2), (CH2)CHO, SCH(CH2), etc. (fragments in parentheses not in ring); X = O, S, CR6R7, CH2CH2, CH:CHCH2, COCH2, OCH2, CH2O, SCH2, NR8, NR9, etc.; q, p = 0, 1; r = 1-3; m = 1, 2; n = 1 when m = 1; n = 0 when m = 2; R3, R4 = H, or R3R4 = bond when m = 2; R5 = OH, alkoxy; R6-R9 = H, alkyl] and their pharmaceutically acceptable salts are disclosed. The invention also relates to esters of I, methods of preparation of I, compns. containing the compds., and their use for the clin. treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiol. role by eliciting neurogenic pain or inflammation. For example, 6,11-dihydro-5H-dibenz[b,e]azepine was subjected to a sequence of: N-acylation with ClCH2CH2COCl (100%), reduction of carbonyl with LiAlH4, amination of the chloride with (R)-3-piperidinecarboxylic acid Et ester tartrate (42%), and alkaline hydrolysis and acidification of the ester (74%), to give title compound II.HCl. At 0.1 mg/kg in mice, II.HCl gave 36% inhibition of formalin-induced paw pain response.

IT 183614-96-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of tricyclic azaheterocyclic carboxylic acids as analgesics and antiinflammatories)

RN 183614-96-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-(6,11-dihydro-6,11-dioxo-5H-dibenz[b,e]azepin-5-yl)propyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 183614-62-2P 183614-69-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic azaheterocyclic carboxylic acids as analgesics and antiinflammatories)

RN 183614-62-2 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[3-(6,11-dihydro-6,11-dioxo-5H-dibenz[b,e]azepin-5-yl)propyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 183614-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[3-(6,11-dihydro-6,11-dioxo-5H-dibenz[b,e]azepin-5-yl)propyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1994:134252 CAPLUS Full-text
DN 120:134252
OREF 120:23639a,23642a
TI New [dibenzo[b,e]azepin-5-yl]acetamides with anticonvulsant activity
AU Viti, G.; Giannotti, D.; Altamura, M.; Ricci, R.; Volterra, G.; Lecci, A.; Borsini, F.; Pestellini, V.
CS Chem. Dep., Menarini Srl, Florence, Italy
SO European Journal of Medicinal Chemistry (1993), 28(5), 439-45
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
OS CASREACT 120:134252
GI



I

AB Title compds., e.g. I [R1 = NH2, NHMe, NHEt, NMe2, NEt2, NHCHMe2, cyclopropylamino, 3-F3CC6H4NH, pyrrolidino, morpholino, 3-carbamoylpiperidino, 4-methylpiperazino, 4-(3-trifluoromethylphenyl)piperazino, R2 = H, Cl, X = O, CH2, H,OH, H,OEt], were prepared via amidation reactions of I (R1 = OH) and tested for anticonvulsant activity. Many I are more potent than ethosuximide and display relatively low neurotoxicity.
IT 153007-15-9P 153007-16-0P 153007-17-1P
153007-18-2P 153007-19-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)(preparation and anticonvulsant activity of)
RN 153007-15-9 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 153007-16-0 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-(4-morpholinyl)-2-oxoethyl]- (CA INDEX NAME)



RN 153007-17-1 CAPLUS
CN 3-Piperidinecarboxamide, 1-[2-(6,11-dihydro-6,11-dioxo-5H-dibenz[b,e]azepin-5-yl)acetyl]- (CA INDEX NAME)



RN 153007-18-2 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



RN 153007-19-3 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)


CF3
N
N
C
O
CH2
O
N
O

L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:203129 CAPLUS Full-text
DN 116:203129
OREF 116:34259a,34262a
TI Spectroelectrochemistry of aromatic ligands and their derivatives. III. Binuclear transition metal complexes of copper(I), molybdenum(0), and rhenium(I) with 2,2'-bipyrimidine. [Erratum to document cited in CA116(2):12392f]
AU Braterman, Paul S.; Song, Jae Inh; Kohlmann, Stephan; Vogler, Conny; Kaim, Wolfgang
CS Dep. Chem., Univ. North Texas, Denton, TX, 76203-5068, USA
SO Journal of Organometallic Chemistry (1992), 424(1), C2
CODEN: JORCAI; ISSN: 0022-328X
DT Journal
LA English
AB Errors in Table 1 have been corrected The errors were not reflected in the abstract or the index entries.
IT 1242-73-5
RL: PRP (Properties)
(electrochem. reduction and visible spectra of (Erratum))
RN 1242-73-5 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1992:12392 CAPLUS Full-text
DN 116:12392
OREF 116:2159a,2162a
TI Spectroelectrochemistry of aromatic ligands and their derivatives. III. Binuclear transition metal complexes of copper(I), molybdenum(0), and rhenium(I) with 2,2'-bipyrimidine
AU Braterman, Paul S.; Song, Jae Inh; Kohlmann, Stephan; Vogler, Conny; Kaim, Wolfgang
CS Dep. Chem., Univ. North Texas, Denton, TX, 76203-5068, USA
SO Journal of Organometallic Chemistry (1991), 411(1-2), 207-13
CODEN: JORCAI; ISSN: 0022-328X
DT Journal
LA English
AB The binuclear complexes [Mo(CO)4]2(bpym) (I), [Re(CO)3Cl]2(bpym) (II), and [[Cu(PPh3)2]2(bpym)]2+ (III) (where bpym is bipyrimidine) were subjected to 1- and (for I, III) 2-electron reduction, and the products were studied in situ by UV-Vis-NIR spectroscopy. The spectra were assigned in terms of a simple HMO scheme, in which the reduction orbital is ligand $\pi(7)$, related to $\pi(7)$ of biphenyl, the transition $\pi(6) \rightarrow \pi(7)$ moves to lower energy on successive reduction, and bands observed in the near IR-visible region are due to transitions from $\pi(7)$ to higher unoccupied orbitals. Detailed assignments are directly related to those of other singly and doubly reduced azabiphenyls; the bpym dianion was characterized for the 1st time.
IT 1242-73-5
RL: PRP (Properties)
(electrochem. reduction and visible spectra of)
RN 1242-73-5 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1965:29635 CAPLUS Full-text
DN 62:29635
OREF 62:5255g-h
TI Derivatives of morphanthridine
AU Werner, L. H.; Ricca, S.; Mohacsi, E.; Rossi, A.; Arya, V. P.
CS CIBA Corp., Summit, NJ
SO Journal of Medicinal Chemistry (1965), 8(1), 74-80
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB The Schmidt reaction products of monosubstituted anthraquinones were studied. The resulting mixts. of isomeric morphanthridine-6,11-diones were separated by crystallization and the structure of some of the isomers was determined Reduction of morphanthridine-6,11-dione (I) gave 6-morphanthridone (II) and 5,6-dihydromorphanthridine. The 5-dialkylaminoalkyl derivs. of I and of II showed interesting antispasmodic activity; 5-(2-imidazolinylmethyl)-5,6-dihydromorphanthridine (III) was of particular interest because of its effect on aconitine-induced cardiac arrhythmias.
IT 1242-73-5P, 6,11(5H)-Morphanthridinedione, 5-(2-piperidinoethyl)-, hydrochloride
RL: PREP (Preparation)
(preparation of)
RN 1242-73-5 CAPLUS
CN 5H-Dibenz[b,e]azepine-6,11-dione, 5-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L2              QUE  ABB=ON  PLU=ON  L1


     (FILE 'HOME' ENTERED AT 19:22:02 ON 17 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 19:22:23 ON 17 JUL 2009
L1              STRUCTURE UPLOADED
L2              QUE L1
L3           13 S L2
L4          159 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 19:23:07 ON 17 JUL 2009
L5           10 S L4


COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                57.40     243.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -8.20      -8.20

STN INTERNATIONAL LOGOFF AT 19:24:15 ON 17 JUL 2009
```